surmount-1 tirzepatide obesity nejm 2022 weight loss percent In the trial (published in in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor Tirzepatide for Heart Failure with
Description
Use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose)
But, healthcare providers need to monitor how well it works
The Science: GLP-1 vs
But retatrutide is not yet FDA approved
No supplier endorsement For prescription compounded tirzepatide, verify the clinician, prescription, and pharmacy directly
